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ABSTRACT
The purpose of this trial was to define the maximum tolerated duration (MTD), dose-limiting toxicity (DLT),
regimen-related toxicities (RRT), and pharmacokinetics of gemcitabine infused at a fixed dose rate (FDR) of
10 mg/m2/min, combined with docetaxel/melphalan/carboplatin, using autologous stem cell transplantation
(ASCT). The duration of gemcitabine infusion was incrementally escalated as a single treatment on day 6 or
as 4 daily infusions on days 5 to 2. Gemcitabine was followed by docetaxel (300 or 350 mg/m2) on day 5,
and then melphalan (50 mg/m2/day) and carboplatin (333 mg/m2/day) on days4 to2. Fifty-two patients with
refractory tumors were accrued with a median age of 40 (range: 6-66), a median of 3 (1-6) prior chemotherapy
regimens, and 3 (1-7) organs involved. The gemcitabine MTD was defined at 20 hours (total dose 12,000
mg/m2) on both schedules. The DLT was enteritis. Three patients died from aspiration, catheter-related
sepsis, and enteritis, respectively. The tumor response rate was 91%, with 50% complete responses. At current
2-year median follow-up, the event-free and overall survival (EFS, OS) rates are 54% (median 26 months) and
79% (median not reached), respectively. Gemcitabine area under the curve (AUC), but not clearance, increased
linearly with infusion duration, and correlated with grade 3 RRT. Docetaxel showed a linear increase of its
AUC and similar clearance compared with prior reports at lower doses. In conclusion, ASCT-supported
infusions of gemcitabine at FDR could be prolonged up to 20 hours. The resulting gemcitabine/docetaxel/
melphalan/carboplatin combination was highly active in refractory cancers and should be further tested in
disease-specific trials.
© 2007 American Society for Blood and Marrow Transplantation
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Tumor relapse constitutes the major cause of fail-
re after high-dose chemotherapy (HDC) and autol-
gous stem cell transplantation (ASCT). Most classi-
al HDC regimens are based on alkylating drugs, c
324hich show a steep concentration-response effect in
itro, but only modest intrinsic antitumor activity for
any diseases. New synergistic HDC regimens com-
ining drugs with favorable toxicity and dose-response
roﬁles, and greater activity in vivo may improve out-
ome [1].
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High-Dose Gemcitabine at FDR with ASCT 1325Gemcitabine is a nucleoside analog with an ade-
uate proﬁle for high-dose testing. It has broad clin-
cal antitumor activity in solid tumors and lymphomas,
nd little extramedullary toxicity. In vitro experiments
ave suggested a dose-response relationship [2,3]. In
ivo models have shown an antitumor effect that is
ighly dependent on both dose and duration of expo-
ure [4,5].
Gemcitabine is inactivated in plasma into 2=,2=-
eoxydiﬂuorouridine (dFdU) or activated intracellu-
arly into its triphosphate metabolite (dFdCTP),
hich is incorporated into DNA and is largely respon-
ible for its cytotoxic effect [6]. The activating en-
yme, deoxycytidine kinase, becomes saturated when
emcitabine plasma levels exceed 20 to 30 mol/L [7].
nfusing gemcitabine at a ﬁxed dose rate (FDR) of
0 mg/m2/min seems to optimize the formation of
FdCTP [8-10]. Randomized trials comparing lower
ose FDR infusions over 75 to 150 minutes with
igher dose infusions over 30 minutes have shown a
ubstantial pharmacokinetic advantage for the former,
hich resulted in a 2-fold greater accumulation of
FdCTP, albeit with increased hematologic, but not
xtramedullary, toxicities [11,12].
The use of ASCT circumvents myelotoxicity and
llows for major dose escalations of agents whose main
oxicities at standard doses are medullary. We hypoth-
sized that ASCT would allow signiﬁcant prolonga-
ion of gemcitabine infusion at FDR when added to an
stablished HDC regimen. We chose to combine pro-
onged FDR gemcitabine with the docetaxel, melpha-
an, and carboplatin (DMC) regimen because of our
revious experience, in which we saw marked activity
nd a manageable side-effect proﬁle of DMC [13], and
ecause we wanted to exploit the reported synergy
etween these agents and gemcitabine [14-18]. We
eport here the results of a phase I trial of FDR
emcitabine plus DMC and ASCT.
ATIENTS AND METHODS
atient Population
The study protocol was approved by the institu-
ional review board of the Clínica Universitaria de
avarra, where all patients were treated. All patients
ave written informed consent before study entry.
he study endpoints were to deﬁne the maximum
olerated duration (MTD), dose-limiting toxicity
DLT), and regimen-related toxicities (RRT) of the
egimen and the pharmacokinetics of high-dose gem-
itabine and docetaxel.
Eligibility was restricted to patients with advanced
ancers refractory to standard chemotherapy. Patients
ith breast cancer met at least 1 of the following
riteria: tumor progression while on chemotherapy,
o response after 2 or more chemotherapy regimens hor metastatic disease, unresponsive liver metastases,
elapse within an irradiated ﬁeld, or prior HDC. Pa-
ients with non-Hodgkin lymphoma (NHL) or germ-
ell tumors were eligible if their disease was refractory
o ﬁrst-line or salvage chemotherapy. Patients with
odgkin disease were required to be in refractory
elapse. Patients with other chemorefractory diseases
ere also eligible.
Pretransplant staging tests included chest, abdo-
en, and pelvis CT scans, head MRI, bone scan, and
ilateral bone marrow aspirate and biopsies. In addi-
ion, a positron emission tomography (PET)/CT was
erformed in HL and NHL patients. General physical
nclusion criteria were full recovery from acute toxic
ffects of prior therapy, performance status of 0 to 1,
nd acceptable end-organ performance, deﬁned as the
ollowing: creatinine clearance 60 mL/min, left
entricular ejection fraction (LVEF) 45%, diffu-
ion capacity of carbon monoxide (DLCO) and
orced expiratory volume 1.0, 60% of predicted,
iver function tests (aspartate transaminase, alanine
ransaminase and bilirubin levels) 2 times their
pper normal limits, and acceptable bone marrow
unction (white blood cell count 3000/mm3 with
bsolute neutrophil count 1000/mm3, and platelet
ount 100,000/mm3). The previous cumulative
oxorubicin dose was limited to 450 mg/m2. Any prior
reatment with docetaxel, gemcitabine, melphalan, or
arboplatin was allowed. Apheresis of a minimum of 1
illion CD34 cells/kg after peripheral blood pro-
enitor cell (PBPC) mobilization with granulocyte-
olony stimulating factor (G-CSF), with or without
hemotherapy, was required.
reatment
The treatment schema is shown in Table 1. Upon
dmission on day 6, patients received dexametha-
one at 8 mg by mouth (p.o.) or intravenously (i.v.)
wice a day (b.i.d.) for 8 doses. Patients in cohorts 1 to
received FDR (10 mg/m2/min) gemcitabine by i.v.
nfusion from day 6, starting at varying times in the
M, until day 5 at 9 AM. After the gemcitabine
nfusion was completed, docetaxel was infused i.v. over
hours at 300 (cohorts 1 to 3) or 350 mg/m2 (cohorts
to 7) on day 5. Melphalan was infused i.v. over 15
inutes at 50 mg/m2/day on days 4, 3, and 2.
arboplatin was administered over 2 hours i.v. at 333
g/m2/day on the same days and starting at the same
ime as melphalan. The area under the curve (AUC) of
arboplatin was estimated retrospectively using the
ockroft-Gault [19] and Calvert [20] formulae to cal-
ulate the glomerular ﬁltration rate, with a maximum
ormal value of 120 mL/min, and the carboplatin
xposure, respectively.
After the MTD of gemcitabine was deﬁned at 20
ours, the protocol was amended to include a seventh
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Y. Nieto et al.1326ohort of patients who received gemcitabine as a daily
-hour i.v. infusion on days 5 to 2 (total duration,
0 hours; total dose, 12,000 mg/m2), followed by do-
etaxel (day 5) and then melphalan and carboplatin
days 4, 3, and 2) at the aforementioned doses.
Hydration was maintained with 0.9% saline ad-
inistered at 100 mL/hour from day 6 to day 5
M, and at 250 mL/hour thereafter until day1. The
nfusion of PBPC was on day 0. Five patients with
one marrow involvement received a CD34-selected
ell product. Supportive care was uniform. For infec-
ious prophylaxis, we used levoﬂoxacin (500 mg p.o./
.v. daily from day 1), acyclovir (800 mg p.o. or 5
g/kg i.v. b.i.d. from day 1 to day 45), and ﬂu-
onazole (200 mg p.o./i.v. daily from day 1 until
eutrophil engraftment). Febrile neutropenia was
reated with cefepime at 2000 mg i.v. 3 times a day
t.i.d.) and vancomycin (1000 mg i.v. b.i.d.), and am-
hotericin B lipid complex (3 mg/kg i.v. daily) if no
efervescence after 96 hours. After 2 cases of fatal
epsis by cefepime-resistant Escherichia coli occurred,
eropenem (1000 g i.v. t.i.d.) was substituted for
efepime. Several toxicities we previously noted with
MC [13] were managed as follows: oral cryotherapy
ith ice chips during the melphalan infusions [21-23],
nd glutamine mouthwashes (10 g 4 times a day) from
ay 1 until neutrophil engraftment [24-26] were
sed to prevent and treat stomatitis, respectively. To
revent engraftment syndrome patients received
-methylprednisolone at 20 mg i.v. b.i.d. from day 1
o day 7 [27]. Neostigmine at 2 mg i.v. over 5
inutes [28] was considered for patients with ady-
amic ileus. Myoarthralgia was treated with tramadol
r morphine. Hand-foot syndrome was treated with
yridoxine 50 mg p.o. t.i.d. Gabapentin was used for
europathic pain at starting doses of 300 mg p.o. at
edtime up to 900 mg p.o. t.i.d. Patients with symp-
omatic hyponatremia, or a serum sodium level 125
Eq/L meeting criteria for syndrome of inappropri-
able 1. Treatment Schema
6 
emcitabine at FDR
Over 9-20 hours (cohorts 1-6) X
Over 5 hours (cohort 7) X
ocetaxel
300 or 350 mg/m2 i.v. over 2 hours X
elphalan
50 mg/m2 i.v. over 15 minutes
arboplatin
333 mg/m2 i.v. over 2 hours
examethasone
8 mg i.v./p.o. b.i.d. X X
SCT
DR indicates ﬁxed-dose rate; i.v., intravenous; p.o., by mouth; b.ite secretion of antidiuretic hormone (SIADH), un- ﬂerwent furosemide-induced diuresis and saline vol-
me replacement. Methylphenidate was considered
or patients with grade 2 or greater asthenia following
ischarge at starting doses of 10 mg with breakfast and
mg at lunchtime [29]. Moisturizing petrolatum was
sed for symptomatic skin rashes.
The pretransplant imaging tests were repeated
wice a year in the ﬁrst 3 years of follow-up and once
year thereafter.
harmacokinetic Analyses
Gemcitabine. Plasma gemcitabine and dFdU were
easured for the single gemcitabine treatment in co-
orts 1-6, and for the ﬁrst and last daily treatments in
atients in cohort 7. Intracellular dFdCTP was only
easured after the ﬁrst and last daily treatments in
ohort 7. Six 5-mL blood samples were taken from
ach patient and drawn into tubes containing heparin
nd 0.5 ng tetrahydrouridine at the following time
oints relative to the gemcitabine infusion: immedi-
tely before infusion, 30 minutes and 3 hours into the
nfusion, 5 minutes before the end of the infusion, and
0 minutes and 19 hours after the end of the infusion.
he samples were placed in ice, centrifuged, and
tored at 70°C. Peripheral blood mononuclear cells
PBMC) were obtained using a Ficoll-Hypaque step-
ensity gradient centrifugation procedure (Sigma
hemical Co., St Louis, MO), and isolated cells were
reserved at70°C. A Coulter counter equipped with
channelyzer (Beckman Coulter Inc., Fullerton, CA)
as used to count the PBMCs.
Gemcitabine, dFdU, and dFdCTP levels were
ssayed by reverse-phase high-performance liquid
hromatography (HPLC) as previously detailed
30], and described using a modiﬁed monocompart-
ental model including an intracellular compart-
ent, using NONMEM software, version V, level
.1. (GloboMax LLC, Hanover, MD). 5=-Deoxy-5-
Day
4 3 2 1 0
X X X
X X X
X X X
X X
X
ce a day; ASCT, autologous stem cell transplantation.5uorouridine, used as the internal standard for the
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High-Dose Gemcitabine at FDR with ASCT 1327emcitabine assay, was purchased from Sigma-Al-
rich (Madrid, Spain) and gemcitabine, dFdU, and
FdCTP were provided by Lilly España (Alcoben-
as, Spain). A sample preparation based on a previ-
usly described procedure with trichloroacetic acid
nd freon:trioctylamine [30], which allows the con-
omitant removal of proteins, nucleic acids, and
ipids, was used. Separation of compounds was
chieved in a C18 reverse-phase analytical column
sing a type of ion-pair reversed-phase HPLC sys-
em with a mixture of triethylamine phosphate
uffer and methanol in gradient elution as a stan-
ard eluent. Elution was performed at 50°C, a ﬂow
ate of 1.2 mL/min, and a detection wavelength set
t 272 nm. Under these conditions, total analysis
ime was 30 min. The lower limits of quantiﬁcation
ere 0.25 g/mL for gemcitabine and dFdU, and 1
g/mL for dFdCTP. The assay had good recovery
nd precision: the within-day and between-days rel-
tive standard deviation of the mean was consis-
ently 10%.
The aggregate AUC of gemcitabine of patients
nrolled in cohort 7 was calculated by multiplying by
the sum of the measured AUCs of treatment days 1
nd 4. Steady-state concentrations (Css) of gemcitab-
ne were calculated as the mean of the concentrations
easured from 30 minutes after the start to 5 minutes
efore the end of the infusion. The intracellular con-
entration of dFdCTP was calculated as the quantity
f nucleotides contained in the extract per 106
BMCs.
Docetaxel. To measure plasma docetaxel levels, we
rew 5-mL venous blood samples into heparin-con-
aining tubes from each patient at the following time
oints: immediately before docetaxel infusion, 60
inutes into the infusion, 5 minutes before the end of
he infusion, and 15 minutes, 45 minutes, 2.5 hours, 6
ours, 12 hours, and 24 hours after the end of the
nfusion. The samples were stored at 30°C before
easurement, for which we used a previously vali-
ated HPLC assay [31]. Paclitaxel was used as the
nternal standard. The overall mean recovery of do-
etaxel using this assay is 88 14%, with a lower limit
f quantiﬁcation of 0.015 mg/L. The intraday and
nterday variation of this assay is 10%. Docetaxel
harmacokinetics were described using a tricompart-
ental model by nonparametric expectation maximi-
ation (NPEM) using the USC PACK 10.7 program
University of Southern California, Los Angeles, CA).
s we previously reported [27], NPEM yields highly
ccurate predictions of docetaxel population pharma-
okinetic parameters (r2  0.985).
ose Escalation
For toxicity scoring, we followed the National
ancer Institute Common Toxicity Criteria, version c.0 [32]. Any nonhematologic RRT greater than grade
was considered DLT. Early stopping rules for ex-
essive toxicity mandated discontinuation of the trial if
of the ﬁrst 10 patients died of RRT. Dose escalation
roceeded according to the “3  3” algorithm: 3
atients were enrolled at each dose level, and if none
xperienced DLT, escalation would proceed. If 1
atient experienced DLT, at least another 3 patients
ere to be enrolled in that cohort. If 2 of 6 patients in
ne cohort experienced DLT, that dose would be
onsidered unacceptably toxic and gemcitabine would
e de-escalated 1 step. The MTD was deﬁned as the
ongest duration of infusion causing DLT in either
1 case of 6 patients, or in 20% patients if more
han 6 patients were enrolled in 1 cohort.
tatistical Analyses
Objective responses were evaluated at 4 weeks
fter HDC following current guidelines for solid tu-
ors [33] and lymphomas [34]. Follow-up time was
he time from HDC to last visit for the patients alive.
vent-free survival (EFS) was estimated from the ﬁrst
ay of HDC until tumor progression, relapse, or
eath from any cause. Overall survival (OS) was esti-
ated from HDC start until death.
The relationships between gemcitabine and do-
etaxel doses and pharmacokinetic parameters were
ssessed by using a Spearman rank correlation test.
his test was also used to compare the pharmacoki-
etic parameters of docetaxel in this study with those
rom prior reports using lower doses, ranging from 35
o 175 mg/m2 [35-38]. The Student t-test was used to
ompare the dFdCTP AUC on day 5 and day 2,
nd to compare pharmacokinetic parameters in pa-
ients with and without grade 3 toxicity. The statistical
nalyses were performed using Statistica software ver-
ion 6.1 (StatSoft, Tulsa, OK).
ESULTS
atient Enrollment
Fifty-two patients were enrolled between October
004 and May 2006. Patient characteristics are listed
n Table 2. They were heavily pretreated (median 3
rior regimens) and had extensive tumor involvement
median 3 organs). Their diagnoses included breast
ancer (N  31), Ewing’s sarcoma (N  5), NHL
N  4), germ-cell tumor (N  4), Hodgkin disease
N  3), soft tissue sarcoma (N  3), Wilms’ tumor
N  1), and osteosarcoma (N  1).
The escalation of gemcitabine infusion escalation
roceeded as shown in Table 3. After completing
nrollment in the sixth cohort (20-hour infusion), this
ose level was designated the MTD with no further
scalation, based on events described below. A seventh
ohort of 17 patients was then treated with a 20-hour
c
f
R
T
s
d
s
s
w
o
t
s
r
c
c
o
b
a
4
w
c
i
d
bl
e
3.
G
ra
de
2
or
G
re
at
er
N
on
he
m
at
ol
og
ic
T
ox
ici
tie
s
ho
rt
G
em
D
tx
M
el
C
ar
bo
N
T
o
xi
c
D
ea
th
s
S
to
m
at
it
is
E
nt
er
o
co
lit
is
C
o
ns
ti
pa
ti
o
n/
Il
eu
s
D
ia
rr
he
a
M
/A
P
N
P
S
ki
n
R
as
h
H
F
S
R
en
al
A
S
T
/A
L
T
E
le
va
ti
o
n
S
IA
D
H
O
ny
ch
o
ly
si
s
A
st
he
ni
a
(P
o
st
di
s
ch
ar
ge
)
1
9
h
30
0
15
0
10
00
3
1
G
2
1
G
2
1
G
2
1
G
2
1
G
2
2
12
h
30
0
15
0
10
00
11
1
4
G
2
3
G
2
7
G
2
3
G
2
1
G
2
4
G
2
1
G
2
4
G
2
(a
sp
ir
at
io
n)
2
G
3
1
G
3
1
G
3
3
15
h
30
0
15
0
10
00
3
1
G
2
1
G
2
1
G
2
1
G
2
1
G
2
1
G
3
4
15
h
35
0
15
0
10
00
3
1
G
2
1
G
2
2
G
2
1
G
2
1
G
2
1
G
2
1
G
2
1
G
3
5
18
h
35
0
15
0
10
00
7
4
G
2
1
G
2
1
G
2
2
G
2
2
G
2
2
G
2
2
G
2
2
G
3
1
G
3
6
20
h
35
0
15
0
10
00
8
1
2
G
2
1
G
3
1
G
3
1
G
2
5
G
2
5
G
2
1
G
2
2
G
3
2
G
2
1
G
3
2
G
2
5
G
2
(s
ep
si
s)
3
G
3
1
G
3
3
G
3
7
20
h
35
0
15
0
10
00
17
1
11
G
2
1
G
2
1
G
3
2
G
2
11
G
2
4
G
2
4
G
2
1
G
3
6
G
2
4
G
2
9
G
2
(e
nt
er
it
is
)
5
G
3
2
G
3
2
G
3
2
G
3
4
G
3
1
G
5
m
in
di
ca
te
s
ge
m
ci
ta
bi
ne
;
D
tX
,
do
ce
ta
xe
l;
M
el
,
m
el
ph
al
an
;
C
ar
bo
,
ca
rb
op
la
tin
;
M
/A
,
m
yo
ar
th
ra
lg
ia
;
P
N
P
,
pe
ri
ph
er
al
ne
ur
op
at
hy
;
H
FS
,
ha
nd
-f
oo
t
sy
nd
ro
m
e;
A
ST
,
as
pa
rt
at
e
tr
an
sa
m
in
as
e;
A
L
T
,
al
an
in
e
tr
an
sa
m
in
as
e;
SI
A
D
H
,s
yn
dr
om
e
of
in
ap
pr
op
ri
at
e
se
cr
et
io
n
of
an
tid
iu
re
tic
ho
rm
on
e;
G
,g
ra
de
.
T
A
S
D
N
N
Y. Nieto et al.1328umulative infusion of gemcitabine divided into 5-hour
ractions over 4 treatment days (day 5 to 2).
egimen-Related Toxicities
The major nonhematologic toxicities are shown in
able 3. Three treatment-related deaths were ob-
erved, 1 each in cohorts 2, 6, and 7. The ﬁrst patient
ied from aspiration, probably associated with over-
edation, in the absence of major concurrent RRT; the
econd 1 died from multidrug-resistant E. coli sepsis,
hich originated in the catheter based on the results
f semiquantitative blood cultures; and the third pa-
ient died from enteritis and multidrug-resistant E. coli
epsis. Although neither of the ﬁrst 2 deaths was di-
ectly attributed to RRT, we hypothesized that sub-
linical enteritis might have caused bacterial translo-
ation into the bloodstream and subsequent infection
f the catheter in the second patient. Thus, sepsis
elieved secondary to intestinal mucosal injury was
ssigned to be dose limiting. No other cases of grade
or 5 toxicity occurred. The observed side effects
ere not different between cohorts 6 and 7, with a
ombined 28% incidence of grade 3 or greater enter-
tis/diarrhea in 25 patients. Overall, the regimen pro-
able 2. Patient Demographics (N  52)
ge: median (range) 40 (6-66)
ex
Female 37
Male 14
iagnoses
Breast cancer 31
Ewing’s sarcoma 5
Germ-cell tumors 4
Non-Hodgkin lymphoma 4
Hodgkin disease 3
Soft-tissue sarcoma 3
Osteosarcoma 1
Wilms’ tumor 1
umber of prior chemotherapy regimens:
median (range) 3 (1-6)
Prior gemcitabine 5
Prior docetaxel 14
Prior taxanes 28
Prior high-dose chemotherapy 3
umber of organs involved: median (range) 3 (1-7)
Peripheral lymph nodes 24
Lungs 19
Bone 17
Liver 13
Mediastinum 12
Soft tissue 8
Retroperitoneum 6
Bone marrow 5
Pleura 3
Central nervous system 1
Bladder 1
Peritoneum 1uced the following clinical proﬁle of side effects. Ta C
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High-Dose Gemcitabine at FDR with ASCT 1329Mucositis. It started early after ASCT, peaked at a
edian of day 2, and lasted at its maximal severity
or a median of 4 days. The median total number of
ays of narcotic use was 7 (range: 0 to 16).
Diarrhea. It presented in the second week and
esponded promptly to antidiarrheals. In 1 case there
as fecal incontinence. Perirectal exams did not evi-
ence sensory deﬁcits in any patient.
Enterocolitis. It occurred in the second week, last-
ng for a median of 5 (range: 2 to 7) days. Two patients
equired readmission following discharge (on day18
nd day 35) and were hospitalized for up to 2 weeks.
Constipation/ileus. Two cases of grade 3 ileus in the
econd week were managed successfully with neostig-
ine.
Myoarthralgia. Early (median onset on day 3)
yoarthralgia was frequent in all cohorts, responded
romptly to analgesics, and lasted for a median of 2
ays (range: 1 to 7 days) at peak severity.
Peripheral neuropathy. Thirteen patients in the en-
ire study, 9 of them receiving gemcitabine at the
TD, experienced grade 2 peripheral neuropathy,
ith resolution or signiﬁcant recovery in the ﬁrst few
eeks after discharge. Six patients in the entire study
ad neuropathic pain, which responded to gabapentin.
Skin effects. Grades 2 and 3 erythematous rashes
ere seen in 5 and 2 patients, respectively, treated at
he gemcitabine MTD. The rashes appeared in the
rst week after the ASCT, and were asymptomatic or
ere easily relieved with moisturizing petrolatum, and
esolved within a few days. Additionally, 2 cases of
rade 3 hand-foot syndrome had a similar time course
nd quick symptomatic response to treatment with
yridoxine.
Hepatic effects. An early and transient elevation of
ransaminases was noticed across all study cohorts in
0 patients, reaching a median peak value of 168 IU/L
range: 60 to 599). It started on median day 3,
eaked on median day 1, and resolved within 1
eek.
Asthenia. Grade 2 asthenia in 23 patients was the
ost prominent postdischarge symptom. Most cases
esponded rapidly to methylphenidate.
Nail effects. Twelve patients in the entire study
eveloped partial onycholysis. In all cases, nails grew
ack within 2 to 3 months.
Renal effects. One patient in cohort 7 developed
rade 3 acute renal failure requiring hemodialysis for
ess than 2 week.
SIADH. One patient, treated with 350 mg/m2 of
ocetaxel developed asymptomatic SIADH on day
2, which responded to treatment within 24 hours.
Effects on other vital organs. No cardiac, cerebral, or
ulmonary RRT were observed during the study. Me-
ian pre- and posttransplant LVEF were 60% (range:
7% to 73%) and 58% (range: 42% to 72%), respec-
ively (P  .1). Median pre- and posttransplant sLCO were 82% (range: 64% to 111%) and 79%
range: 79% to 121%) (P  .15).
Infections. Two cases of fatal multidrug-resistant E.
oli sepsis were seen, associated with the catheter and
nteritis, respectively. Four cases of antibiotic-sensi-
ive bacteremia (3 with E. coli, 1 with K. pneumoniae)
esolved without complications. Twenty-ﬁve patients
ad positive blood cultures for S. epidermidis (n  23),
. distasonis (n  1), and A. xylosoxidans (n  1).
Two patients had fungemia (1 case each of isola-
ion of Candida krusei and Candida albicans). One pa-
ient developed a suspected fungal pneumonia. All 3
esponded favorably to treatment with amphoteri-
in-B lipid complex, caspofungin, or both.
ematologic Recovery
Patients were infused a median number of 6.2
range: 1.2 to 35) million CD34/kg. Neutrophil
ounts dropped to 100/mm3 on median day 0
range: day 2 to day 2), and platelet counts
ropped to 20,000/mm3 on median day 3 (range:
ay 1 to day 5). One patient who received a
D34-selected product with a prefreezing count of
1.6 million CD34/kg experienced graft failure; she
as subsequently infused with her unselected back-up
ell product with neutrophil and platelet engraftment
5 and 38 days later, respectively. Two patients died
efore engraftment. The remaining 49 patients, in-
luding the other 4 who received a CD34-selected
BPC, experienced prompt engraftment of neutro-
hils on median day 8 (range: day 6 to day 10)
nd platelets on median day 12 (range: day 8 to
ay33). There was no relationship between the dose
evel of gemcitabine and the neutrophil or platelet
ngraftment rates.
ctivity
Thirty-one of 34 patients (91.1%) with measur-
ble disease responded to gemcitabine-DMC in the
ssessment of response at 4 weeks after HDC. Of
hese, 17 (50%) had a complete response, 5 of which
ere pathologically documented. The median dura-
ion of response is 19 (range: 4 to 30) months.
omplete responses were seen in 6 of 12 patients with
easurable breast cancer, 2 of 3 with NHL, 3 of 3
ith Hodgkin disease, 3 of 3 with germ-cell tumors, 1
f 1 with Wilms’ tumor, 1 of 2 with soft tissue sar-
oma, and 1 of 4 with Ewing’s sarcoma. There were
o apparent differences according to the dose level of
emcitabine or docetaxel (data not shown). There
ere no differences in overall response or complete
esponse rate between patients with and without pre-
ious exposure to docetaxel or taxanes in this limited
ample (data not shown).
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Y. Nieto et al.1330lanned Post-HDC Treatment
Eleven patients subsequently received a second
DC cycle, using cyclophosphamide/thiotepa/carbo-
latin (n  4), ifosfamide/carboplatin/etoposide (n 
), busulfan/melphalan (n  2), cyclophosphamide/
itoxantrone/carboplatin (n  1), or melphalan/eto-
oside (n  1), within 3 months of their ﬁrst trans-
lant and tolerated without difﬁculty.
Following platelet recovery after HDC, a total of
2 patients received radiotherapy to previously docu-
ented sites of metastases: bones (n  11), mediasti-
um (n 8), chest wall (n 9), retroperitoneum (n
), bladder (n  1), and lung (n  1), at doses of 30 to
5 Gy.
In the group of patients with breast cancer, 9 of
hem received posttrasplant radiotherapy, 2 with hor-
one receptor-positive breast cancer were prescribed
n aromatase inhibitor, and 14 patients received both.
hree patients with CD20-positive NHL received 4
eekly doses of rituximab starting 6 weeks after HDC.
fourth patient with NHL, who was in partial re-
ponse after gemcitabine-DMC, achieved a complete
esponse after 1 dose of 90Yttrium-ibritumomab tiux-
tan administered at 3 months after transplant.
atient Outcome
At current median follow-up of 24 (range: 13 to
3) months, 78.8% of patients are alive, 53.8% of
hem without evidence of disease (Figure 1). The
edian EFS is 26 months. The median OS has not yet
een reached. One patient with breast cancer, with a
rior history of NHL in remission for more than 10
ears, underwent resection of a primary appendicealFigure 1. EFS and O) curves at meddenocarcinoma 16 months after HDC; she currently
as no clinical evidence of any of her 3 different
etachronous tumors.
harmacokinetic Analyses
The results of the pharmacokinetic analyses are
hown in Table 4. Gemcitabine and dFdU pharmaco-
inetics in plasma were analyzed in 45 patients (Figure
A and B). The AUC of gemcitabine increased lin-
arly with the duration of infusion from 9 to 20 hours
r2  0.71, P  105) (Figure 3A). In contrast, there
ere no differences in clearance (r2  0.005, P  .6)
Figure 3B), maximum concentration (Cmax) (P .14),
olume of distribution (Vd) (P  .95), or half life (t1/2)
P  .85) or Css (P  .37) throughout the study
ohorts. There were no signiﬁcant differences in any
arameter between cohorts 6 (single 20-hour infusion)
nd 7 (4 daily 5-hour infusions). The mean Css of
emcitabine was 26.5 mol/L (standard deviation
SD] 5), similar to those of prior reports using shorter
nfusions of gemcitabine at FDR. The average volume
f distribution of gemcitabine was 59.8 L (SD, 17),
nd its elimination t1/2 was 16 minutes (SD 3), indicat-
ng that, regardless of the duration of infusion, gemci-
abine was widely distributed in the tissues and elimi-
ated rapidly. The clearance of the inactive metabolite
FdU was estimated at 25 L/h, with a Vd of 37 L.
The intracellular levels of the active metabolite
FdCTP were measured on the ﬁrst (day 5) and
ourth (day 2) treatment days in 15 patients enrolled
n cohort 7 (Figure 2C). We noted wide variations
etween patients and between both treatment days for
he same patient. On the ﬁrst treatment day (day 5),ian follow-up of 24 months.
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High-Dose Gemcitabine at FDR with ASCT 1331he mean AUC of dFdCTP was 1303 mol · h/106
NC (SD 1268). The mean clearance of dFdCTP
as 8.3 L/hr (SD 7.9), with a mean elimination t1/2 of
1 hours (SD 26). Beginning on day 2, the intracel-
ular dFdCTP levels continued to rise in all patients
hroughout its measurements; this continued until
easurements ended at 19 hours after the end of the
nfusion, and the AUC had to be calculated up to the last
easurement point. The mean AUC was 6165
mol · h/106 MNC (SD 5460). Even though the esti-
ation was incomplete, the AUC of dFdCTP was sig-
iﬁcantly higher on day 2 than on day 5 (P  .007).
There was a signiﬁcant correlation between the
lasma AUC of gemcitabine and the intracellular
UC of dFdCTP on day 5 (r2  0.5, P  .01), but
ot on day 2 (r2  0.005, P  .8), although this last
nalysis was complicated by the fact that AUC esti-
ation for dFdCTP after day 2 was incomplete.
hese observations indicate a markedly increased in-
racellular accumulation of dFdCTP over the course
f the 4-day treatment, which may have resulted in
FdCTP levels disproportionate to the plasma levels
f gemcitabine.
Plasma docetaxel was analyzed in 17 patients
reated at 300 mg/m2 and in another 17 patients
reated at 350 mg/m2 (Table 4B). The patients treated
t 350 mg/m2 presented signiﬁcantly higher AUC
18.9 versus 15.5 mg · h/L, P  .01) and Cmax (7.4
ersus 5.7 mg/L, P  .03) than those receiving 300
g/m2. However, docetaxel clearance (38 versus 33 L/h,
 .1) and terminal t1/2 (11.2 versus 9 hours, P  .5)
ere not signiﬁcantly different between the 2 groups.
A comparison of our high-dose docetaxel pharma-
okinetic data with those of prior reports at lower
oses—35 mg/m2 (average AUC, 1.5 mg · h/L; aver-
ge clearance, 43 L/h) [31], 60 mg/m2 (average AUC
able 4. Pharmacokinetic Results of Gemcitabine (4A) and Docetaxel (
Infusion
Duration
AUC
(mg · h · L1)
Cmax
(mg · L1)
hours 73 (9.4) 8.7 (1.3)
2 hours 104.1 (8) 9.25 (1.25)
5 hours 128.2 (18.7) 9.7 (2)
8 hours 134.1 (24.1) 8.2 (2)
0 hours (all ) 148.5 (14.3) 8 (1.4)
ingle infusion 154.7 (10) 8 (0.8)
hours/day  4 145.6 (15.3) 8 (1.6)
Dose
AUC
(mg · h · L1) Cma
00 mg/m2 15.5 (4.3)
50 mg/m2 18.9 (4.4)
UC indicates area under the curve; Cmax, peak levels; Vd, volume o
half life..7 mg · h/L; average clearance, 45 L/h) [32], 75 og/m2 (average AUC 3.4 mg · h/L; average clearance
4 L/h) [32], 100 mg/m2 (average AUC 4.8 mg · h/L;
verage clearance 36 L/h) [33], and 175 mg/m2 (aver-
ge AUC 9.7 mg · h/L; average clearance 34 L/h)
34]—shows a highly linear dose-dependent increase
n the docetaxel AUC (r2  0.86, P  105), with no
hange in clearance across the entire dose spectrum
r2  0.3, P  .13).
The estimated mean AUC of carboplatin in all
atients was 13.6 (SD 2.8) mg/mL · min1.
harmacodynamic Analyses
Sixteen patients who experienced grade 3 RRT
ere exposed to a higher AUC of gemcitabine than
hose who did not experience grade 3 RRT (mean 151
ersus 135 mg · h/L, P  .0005). In contrast, Css
mean 26.9 versus 24.8 mol/L, P  .6) and clearance
mean 133 and 131 L/hr, respectively, P  .8) were
ot different between the 2 groups.
In contrast to the incidence of grade 3 mucositis,
he duration of narcotic requirement did not correlate
ith gemcitabine AUC (P  .2) or dose (P  .3).
There were no signiﬁcant differences in intracel-
ular dFdCTP AUC on day 5 and day 2 between
hose patients in cohort 7 who experienced grade 3
oxicity and those who did not (P  .5 and .3, respec-
ively).
There was a trend for increased docetaxel AUC
mean, 22.3 versus 17.9 mg · h/L, P  .06) and lower
learance (mean, 27.5 versus 35.1 L/h, P .06) among
atients who presented a grade 3 RRT versus those
ho did not.
There was no association of any gemcitabine or
ocetaxel pharmacokinetic parameter with achievement
pressed as Mean (Standard Deviation)
ance
h1)
Vd
(L)
t1/2
(min)
Css
(mol · L1)
(24.2) 63.7 (11.3) 18.2 (1.2) 26.6 (4.9)
(21) 56.9 (16.7) 15.9 (3.7) 30 (4)
(34.4) 60.8 (26.6) 15 (3.4) 28.4 (6.3)
(5.4) 65.7 (5.5) 16 (0.8) 28.4 (6.3)
(21.1) 59.3 (20) 16 (2) 24.8 (3.3
(19.7) 60 (29.2) 16.7 (2.8) 24.8 (3)
(23) 59 (13.5) 15.5 (2.8) 24.4 (4.7)
· L1)
Clearance
(L · h1) t1/2 (hours)
6) 38 (14) 9 (9)
9) 33 (8.9) 11.2 (8.7)
bution; t1/2, half life; Css, steady-state concentration; t1/2, terminal4B), Ex
4A
Clear
(L ·
139.2
122.9
120.2
135
146.6
145.2
147.1
4B
x (mg
5.7 (1.
7.4 (1.
f distrif a complete response or EFS status after transplant.
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Y. Nieto et al.1332ISCUSSION
We found that a substantial prolongation of the
nfusion of gemcitabine at FDR, combined with high-
ose DMC is feasible with ASCT. This regimen
howed high activity in the population of patients with
efractory tumors enrolled in this study, inducing
omplete responses in 50%.
The MTD of gemcitabine was conservatively es-
ablished at 20 hours (total dose, 12,000 mg/m2). Sub-
equently, gemcitabine was infused at its MTD over
he 4 days of treatment, pursuing a DNA damage/
epair inhibition construct that would maximize its
ynergy with carboplatin and melphalan on each of the
igure 2. Pharmacokinetics of gemcitabine in plasma (A), its inact
FdCTP (C). The data correspond to cohort 7 patients on day 5
5. Y axes are expressed in g/mL.treatment days. There were no differences in gem- vitabine pharmacokinetics or toxicity between patients
ho received the MTD in 1 or over 4 days. Most
atients treated at the MTD experienced a manage-
ble side-effect proﬁle of stomatitis, myoarthralgia,
nd diarrhea (with or without enterocolitis) or consti-
ation, all of which peaked early and improved rap-
dly. Moderate asthenia, which was relieved in most
ases by methylphenidate, and peripheral neuropathy
ere the most common posttransplant residual side
ffects. The latter was noticeably less severe than with
he preceding DMC combination [13] (0% versus
5% incidence of grade 3). The lower dose of do-
etaxel in the gemcitabine-DMC combination (350
abolite dFdU in plasma (B), and its active intracellular metabolite
the prolonged decay of the intracellular levels of dFdCTP on dayive met
. Noteersus 400 mg/m2) may account for this observation.
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High-Dose Gemcitabine at FDR with ASCT 1333ikewise, the incidence of SIADH after gemcitab-
ne-DMC (2%) was substantially lower than with
MC (33%).
We saw a linear increase in the AUC of gemci-
abine, which was proportional to the duration of
nfusion, in contrast to its Css and clearance, which
emained constant throughout the study. Our obser-
ations in cohort 7 of greater intracellular levels of
FdCTP after the fourth treatment day compared
ith the ﬁrst day suggest that the activating enzyme,
eoxycytidine kinase, was not saturated in the sched-
le of daily administration of gemcitabine. In contrast,
revious studies of single administrations of gemcit-
bine at FDR in patients with acute myeloblastic leu-
emia showed a decline of the intracellular levels of
FdCTP after around 8 hours of infusion, possibly as
result of deoxycytidine kinase saturation, limiting
he capability of the cells to accumulate dFdCTP
hroughout single long infusions [9,19]. Furthermore,
he increase in dFdCTP we observed throughout the
ractionated daily schedule may reﬂect a self-potenti-
ting mechanism of gemcitabine whereby high levels
f dFdCTP inhibit the inactivating enzyme deoxycy-
idine monophosphate deaminase [6].
Likewise, docetaxel showed a slight but signiﬁcant
ncrement in its AUC as the dose was increased from
00 to 350 mg/m2, with no change in clearance. This
onﬁrms prior observations in a broader array of high
oses of docetaxel tested in our previous phase I trial
f this drug [13]. Further, a comparison of our data
ith those of prior reports at doses from 35 to 175
g/m2 [35-38], shows a remarkably linear dose-de-
endent effect on AUC but no effect on its clearance,
ndicating that the metabolic disposition of docetaxel
s not saturated throughout its dose range.
The activity of the gemcitabine-DMC combina-
igure 3. Linear pharmacokinetics of prolonged infusions of gem
 105). B, No change of clearance with duration of infusion (r2 
onﬁdence intervals, respectively.ion in the patient population enrolled in this trial sppears promising, and can be attributed to several
actors. First, it builds upon an already active regimen,
MC, which in its original phase I trial produced
7% complete responses, with a short median EFS
ime of 6 months but an encouraging 27% EFS rate at
current median follow-up of 42 months [13]. Sec-
nd, combinations of gemcitabine with docetaxel and
NA-damaging agents are additive or synergistic.
emcitabine, followed by docetaxel, results in syner-
istic tumor cell kill in preclinical models and high
esponse rates in a variety of solid tumors [16,17]. The
echanisms for this augmentation, which is not seen
hen the agents are administered concurrently, re-
ain unclear. However, several molecular interactions
ay account for the increased tumor cell kill caused by
he combination of gemcitabine and DNA-targeting
rugs, particularly platinum agents. For example,
emcitabine may inhibit DNA damage repair by re-
ucing the intracellular pools of deoxynucleotide,
uch as deoxycytidine triphosphate, as well as facili-
ating the formation of platinum-DNA adducts or
nhancing the incorporation of dFdCTP into DNA
14,15]. Whereas more than 1 schedule and sequence
f these agents is active, pretreatment with gemcitab-
ne seems to result in the highest preclinical tumor cell
ill [14]. Third, the daily schedule of gemcitabine
nfusion, as tested in cohort 7 of this trial, results in a
arked intracellular retention of dFdCTP through-
ut treatment, possibly by maximally exploiting its
etabolic self-potentiating mechanisms [6]. Finally, in
reclinical experiments, dexamethasone signiﬁcantly
nhanced the antitumor activity of gemcitabine and
isplatin, possibly by decreasing the tumor’s intersti-
ial ﬂuid pressure and increasing their concentration
n the tumor [39]. Dexamethasone was used in our
e at FDR. A, AUC increase with duration of infusion (r2  0.71,
, P  .6). Solid and dashed lines represent average values and 95%citabin
0.005tudy as the standard premedication for docetaxel, and
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Y. Nieto et al.1334t could have conceivably contributed to the regimen’s
ntitumor activity.
Other authors have studied the possibility of ex-
ending the gemcitabine infusion at FDR without
SCT. Cumulative myelosuppression limited the du-
ation of infusion to 150 minutes in repeated weekly
reatments [40,41]. Evaluation of single treatments of
emcitabine at FDR in patients with leukemia, either
n monotherapy [9] or combined with standard-dose
rinotecan [42], mitoxantrone [43] or ﬂudarabine [44],
stablished a gemcitabine MTD of 12 hours, again
ith myelotoxicity as the DLT. Other side effects
een in these studies were stomatitis and transient
ncreases in values of liver function tests. The use of
SCT obviates the concern for myelotoxicity, allow-
ng dose escalation to explore other limiting toxicities
f prolonged gemcitabine infusion.
Bengala et al. [45] escalated the length of infusion
f gemcitabine at FDR every 2 weeks with ASCT in
3 patients with pancreatic cancer. One case of fatal
ucositis occurred at 7000 mg/m2; this toxic effect
as considered the DLT, and no other cases of grade
or greater extramedullary side effects occurred. That
tudy also found that antitumor activity was inversely
roportional to the gene expression level and serum
ctivity of the catabolizing enzyme cytidine deaminase.
In this trial gemcitabine-DMC has shown prom-
sing activity in patients with refractory NHL, HD,
nd GCT, where HDC plays a role in the treatment of
elapsed disease. Disease-speciﬁc phase II trials of
emcitabine-DMC in these tumors are necessary to
onﬁrm our preliminary observations. Recent results
f standard-dose gemcitabine combinations as salvage
reatment for NHL [46-48], HD [49,50], and GCT
51-53] highlight the emerging role of this agent in
heir management.
A potential limitation of our trial is that, along
ith these tumors, we also enrolled patients with met-
static breast cancer or soft-tissue sarcoma, where
DC is not currently considered part of their con-
entional management. Although most randomized
rials conducted in metastatic breast cancer [54-59], as
ell as their overall analysis [60], have shown signiﬁ-
ant EFS differences in favor of HDC compared to
tandard-dose chemotherapy, only 1 of those trials has
hown an OS beneﬁt to date [57]. Therefore, the
uestion of the efﬁcacy of HDC in MBC still requires
onger follow-up. It is, however, possible that newer
nd more effective synergistic HDC regimens may
onvincingly improve outcome of patients with the
atter diagnoses, in contrast to the results to date using
lassical HDC combinations. All patients enrolled
ere legitimate candidates for a study of this nature
ecause of their lack of curative standard-dose options
nd poor prognosis with classical HDC.
The planned posttransplant treatments, such as
ituximab, aromatase inhibitors, or radiotherapy, werehose typically administered after HDC for CD20-
ositive lymphomas, hormone-receptor breast cancer,
r to bulky lesions, respectively. Although they un-
uestionably inﬂuenced the promising EFS and OS
utcomes, response assessment was performed on day
30, before such posttransplant treatments were ini-
iated. Therefore, the high response and complete
esponse rate seen in this study should be solely at-
ributed to gemcitabine-DMC. In view of its high
ctivity in our population of patients with refractory
ancer and its manageable and reversible toxicity pro-
le, the gemcitabine-DMC regimen is worthy of fu-
ure testing in patients with less resistant disease. Al-
hough we could not detect obvious differences in
ctivity or toxicity between the 2 schedules of gemci-
abine in our study, we consider the fractionated daily
chedule to be the 1 that should be further explored,
ecause of the previously discussed synergy consider-
tions, as well as our observations of lack of saturation
n the accumulation of dFdCTP in our fractionated
aily schedule, in contrast to prior reports using single
ong infusions.
This new regimen could be used as part of a strategy
f sequential cycles of non-crossresistant HDC regi-
ens, or combined with molecularly targeted thera-
eutic agents, building on the synergy between its
hemotherapeutic components and novel agents that
arget growth factor signaling [61] or angiogenesis
athways [62-64].
In summary, FDR infusion of gemcitabine can be
ubstantially prolonged and its dose increased when
he agent is combined with high-dose DMC and sup-
orted by ASCT. Gemcitabine and docetaxel have
inear pharmacokinetic proﬁles when given at high
oses. Given this regimen’s high level of activity, fur-
her investigation in disease-speciﬁc phase II studies is
arranted.
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